calhoun vision is the world leader in adjustable intraocular lens technology. the company's proprietary technology utilizes light to enable surgeons to change the power of a lens after it has been implanted in the eye. this offers the potential to provide unparalleled visual outcomes and customization to the specific visual needs of each patient. calhoun vision's light adjustable lens technology is an investigational device in the united states and requires fda approval before it can be marketed commercially. the company has completed phases i and ii of the required clinical investigation; the third and final phase of study has commenced, and all subjects have been fully enrolled.
Company profile
Ticker
RXST
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CALHOUN VISION INC
SEC CIK
Corporate docs
Subsidiaries
RxSight B.V. • RxSight GmbH ...
IRS number
943268801
RXST stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
22 Apr 24
S-8
Registration of securities for employees
28 Feb 24
8-K
RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance
8 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
RxSight, Inc. Reports Third Quarter 2023 Financial Results
9 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
RxSight, Inc. Reports Second Quarter 2023 Financial Results
7 Aug 23
8-K
Entry into a Material Definitive Agreement
5 Jul 23
Transcripts
RXST
Earnings call transcript
2023 Q4
28 Feb 24
RXST
Earnings call transcript
2023 Q3
9 Nov 23
RXST
Earnings call transcript
2023 Q2
7 Aug 23
RXST
Earnings call transcript
2023 Q1
9 May 23
RXST
Earnings call transcript
2022 Q4
6 Mar 23
RXST
Earnings call transcript
2022 Q3
7 Nov 22
RXST
Earnings call transcript
2022 Q2
9 Aug 22
RXST
Earnings call transcript
2022 Q1
9 May 22
RXST
Earnings call transcript
2021 Q4
8 Mar 22
RXST
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
4
Shelley B Thunen
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Eric Weinberg
6 Mar 24
4
Ilya Goldshleger
6 Mar 24
4
Shelley B Thunen
6 Mar 24
4
Ronald M MD Kurtz
6 Mar 24
4
Shelley B Thunen
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
Ilya Goldshleger
16 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.57 mm | 10.57 mm | 10.57 mm | 10.57 mm | 10.57 mm | 10.57 mm |
Cash burn (monthly) | (no burn) | (no burn) | 4.17 mm | 4.59 mm | 2.66 mm | 3.93 mm |
Cash used (since last report) | n/a | n/a | 28.52 mm | 31.40 mm | 18.19 mm | 26.87 mm |
Cash remaining | n/a | n/a | -17.95 mm | -20.83 mm | -7.62 mm | -16.30 mm |
Runway (months of cash) | n/a | n/a | -4.3 | -4.5 | -2.9 | -4.1 |
Institutional ownership, Q3 2023
82.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 128 |
Opened positions | 27 |
Closed positions | 15 |
Increased positions | 48 |
Reduced positions | 33 |
13F shares | Current |
---|---|
Total value | 704.32 bn |
Total shares | 30.42 mm |
Total puts | 2.10 k |
Total calls | 218.70 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 3.05 mm | $85.14 bn |
Artisan Partners Limited Partnership | 2.44 mm | $67.99 bn |
RxSight I | 2.02 mm | $22.69 mm |
Tamer Anthony | 2.01 mm | $0.00 |
BLK Blackrock | 1.85 mm | $51.68 bn |
Lord, Abbett & Co. | 1.63 mm | $45.37 bn |
Vanguard | 1.43 mm | $39.99 bn |
MS Morgan Stanley | 1.21 mm | $33.79 bn |
Millennium Management | 1.16 mm | $32.38 bn |
Longitude Capital Partners II | 994.31 k | $27.46 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Shelley B Thunen | Common Stock | Sell | Dispose S | Yes | Yes | 51.5 | 543 | 27.96 k | 8,402 |
1 Apr 24 | Shelley B Thunen | Common Stock | Sell | Dispose S | Yes | Yes | 50.37 | 200 | 10.07 k | 8,945 |
1 Apr 24 | Shelley B Thunen | Common Stock | Sell | Dispose S | Yes | Yes | 50.2382 | 662 | 33.26 k | 9,145 |
1 Apr 24 | Shelley B Thunen | Common Stock | Sell | Dispose S | Yes | Yes | 49.8126 | 8,938 | 445.23 k | 9,807 |
1 Apr 24 | Shelley B Thunen | Common Stock | Sell | Dispose S | Yes | Yes | 50.2725 | 800 | 40.22 k | 18,745 |
1 Apr 24 | Shelley B Thunen | Common Stock | Sell | Dispose S | Yes | Yes | 49.8145 | 8,857 | 441.21 k | 19,545 |
1 Mar 24 | Shelley B Thunen | Common Stock | Sell | Dispose S | No | Yes | 57.0327 | 2,473 | 141.04 k | 13,691 |
1 Mar 24 | Shelley B Thunen | Common Stock | Sell | Dispose S | No | Yes | 56.3776 | 6,361 | 358.62 k | 16,164 |
1 Mar 24 | Shelley B Thunen | Common Stock | Sell | Dispose S | No | Yes | 54.945 | 1,166 | 64.07 k | 22,525 |
1 Mar 24 | Shelley B Thunen | Common Stock | Option exercise | Acquire M | No | No | 15.5983 | 10,000 | 155.98 k | 23,691 |
News
Assessing RxSight: Insights From 8 Financial Analysts
11 Apr 24
Needham Reiterates Buy on RxSight, Maintains $64 Price Target
11 Apr 24
Stifel Maintains Buy on RxSight, Raises Price Target to $64
29 Feb 24
JP Morgan Maintains Overweight on RxSight, Raises Price Target to $62
29 Feb 24
Oppenheimer Maintains Outperform on RxSight, Raises Price Target to $61
29 Feb 24
Press releases
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
22 Apr 24
RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
4 Apr 24
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
27 Mar 24
RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference
29 Feb 24
RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
14 Feb 24